Protocol Ledger

NCT05373264 · Phase III · RECRUITING

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

Interventional Phase III clinical trial protocol NCT05373264 sponsored by University Medical Center Groningen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-31 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05373264
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05373264
Protocol FieldVerified Registry Value
NCT IdentifierNCT05373264
Consolidated Lead SponsorUniversity Medical Center Groningen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2024-07-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05373264
Hospital Research SiteLocationSite Profile
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->
Universitätsklinikum LeipzigLeipzig, GermanyOpen Hospital Dossier ->
University Medical Center GroningenGroningen, NetherlandsOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI